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Although there have been considerable advances in phar-macological and device therapies for chronic heart fail-
ure (HF) that have improved both morbidity and mortality, 
there has been relatively little progress in the management of 
decompensated HF, and the mortality of patients hospitalized 
with HF remains high.1
In some patients with decompensated HF, intravenous 
diuretics are safe and well tolerated, but in others may be asso-
ciated with a marked worsening of renal function. In these cir-
cumstances, intravenous organic nitrates are commonly used. 
At low doses, these agents preferentially dilate capacitance 
vessels but, although of lesser magnitude, also dilate resistance 
vessels at higher doses and reduce arterial wave reflection.2 
They usually increase cardiac output (CO). Some patients 
with HF are relatively resistant to organic nitrates, and almost 
all patients rapidly develop tolerance during sustained infu-
sion.3 An effective agent devoid of tolerance would therefore 
be attractive. Unfortunately, several novel pharmacological 
agents that have shown promise in early phase trials have not 
been successful in larger hard end point–driven trials.4,5
Sodium nitrite (NaNO2) has a vasodilator profile that is poten-
tially attractive for the treatment of decompensated HF. In healthy 
subjects, NaNO2 exhibits hypoxic augmentation of its vasodila-
tor properties when administered intravenously or intra-arterially, 
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Background—Nitrite exhibits hypoxia-dependent vasodilator properties, selectively dilating capacitance vessels in healthy 
subjects. Unlike organic nitrates, it seems not to be subject to the development of tolerance. Currently, therapeutic options 
for decompensated heart failure (HF) are limited. We hypothesized that by preferentially dilating systemic capacitance 
and pulmonary resistance vessels although only marginally dilating resistance vessels, sodium nitrite (NaNO2) infusion 
would increase cardiac output but reduce systemic arterial blood pressure only modestly. We therefore undertook a first-
in-human HF proof of concept/safety study, evaluating the hemodynamic effects of short-term NaNO2 infusion.
Methods and Results—Twenty-five patients with severe chronic HF were recruited. Eight received short-term (5 minutes) 
intravenous NaNO2 at 10 μg/kg/min and 17 received 50 μg/kg/min with measurement of cardiac hemodynamics. During 
infusion of 50 μg/kg/min, left ventricular stroke volume increased (from 43.22±21.5 to 51.84±23.6 mL; P=0.003), with 
marked falls in pulmonary vascular resistance (by 29%; P=0.03) and right atrial pressure (by 40%; P=0.007), but with 
only modest falls in mean arterial blood pressure (by 4 mm Hg; P=0.004). The increase in stroke volume correlated 
with the increase in estimated trans-septal gradient (=pulmonary capillary wedge pressure–right atrial pressure; r=0.67; 
P=0.003), suggesting relief of diastolic ventricular interaction as a contributory mechanism. Directionally similar effects 
were observed for the above hemodynamic parameters with 10 μg/kg/min; this was significant only for stroke volume, 
not for other parameters.
Conclusions—This first-in-human HF efficacy/safety study demonstrates an attractive profile during short-term systemic 
NaNO2 infusion that may be beneficial in decompensated HF and warrants further evaluation with longer infusion 
regimens.  (Circ Heart Fail. 2015;8:565-571. DOI: 10.1161/CIRCHEARTFAILURE.114.001716.)
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presumably because it is reduced under hypoxic conditions to 
nitric oxide (NO).6–8 We previously demonstrated that in healthy 
subjects breathing room air, intra-arterial NaNO2 only modestly 
dilated forearm resistance vessels, whereas markedly dilating 
forearm capacitance vessels.6 When these subjects breathed a 
hypoxic gas mixture, the forearm resistance vessel dilation was 
augmented.6 Furthermore, NaNO2 reduced pulmonary vascular 
resistance (PVR) in experimental models of pulmonary hyperten-
sion9 and systemic nitrite infusion substantially ameliorated the 
pulmonary vasoconstriction associated with systemic hypoxemia 
in healthy volunteers.10 Previous studies have suggested that nitrite 
therapy may not be subject to the development of tolerance.7,11
Based on these observations, we hypothesized that intra-
venous NaNO2 infusion may substantially increase venous 
capacitance and reduce PVR in patients with severe HF, 
leading to an increase in CO by relieving external constraint 
to left ventricular filling from the pericardium (pericardial 
constraint) and right ventricle (diastolic ventricular interac-
tion [DVI]), whereas only modestly reducing systemic vas-
cular resistance and therefore resulting in only a minor fall in 
blood pressure. We therefore undertook a proof-of-concept 
study to evaluate the hemodynamic effects of systemic short-
term NaNO2 infusion in patients with severe chronic HF. We 
chose a brief (5 minute) infusion for safety reasons because 
this was a first-in-man use of intravenous nitrite in HF.
Methods
Twenty-five patients with severe chronic HF who were undergoing 
right heart catheterization as part of their heart transplant assess-
ment protocol were recruited to the study. The study conformed to 
the Declaration of Helsinki and was approved by the University of 
Birmingham (ERN10-0247) and Local Research Ethics Committee 
(08/H1207/67). Each patient gave written informed consent after sat-
isfying the inclusion criteria (aged ≥18 years, admission to hospital 
for pulmonary artery catheterization, under the transplant protocol) 
and exclusion criteria (preexisting inotrope therapy, recent (3 months) 
myocardial infarction, G6PD deficiency, and women of child-bearing 
potential or nursing mothers). The patients had a diagnosis of HF 
with reduced left ventricular (LV) ejection fraction (<40%) of vari-
ous etiologies, and all patients were on optimal tolerated standard HF 
therapy (Table 1). Baseline characteristics of the patients enrolled in 
the study are listed in Table 1.
Right Heart Catheterization
Patients were randomized (on a 1:2 basis; Table 2) to receive either 10 
μg/kg/min (group 1; n=8) or 50 μg/kg/min (group 2; n=17) of NaNO2 (Martindale Pharmaceuticals, UK). The patients were then placed in 
a supine position to allow the insertion of a Swanz–Ganz catheter 
via a sheath into the right internal jugular vein under local anesthesia 
with positioning confirmed by fluoroscopy and pressure waveform. 
After 15 minutes of stabilization at baseline, the following pressures 
were measured at end-expiration: pulmonary arterial pressure, pul-
monary capillary wedge pressure (PCWP), and right atrial pressure 
(RAP). The trans-septal pressure gradient (TSG) was estimated as 
PCWP-RAP. CO was measured using the Fick technique from the 
mixed venous and arterial oxygen saturations and from predicted 
oxygen consumption. Systemic vascular resistance (Wood units) was 
calculated as (mean arterial pressure–RAP/CO). Arterial elastance 
(a lumped measure of pulsatile and static LV afterload) was calcu-
lated as (0.9×systolic arterial pressure/stroke volume [SV]).12 Left 
ventricular stroke work was calculated as SV×mean arterial blood 
pressure (MABP). Arterial oxygen saturation was measured by pulse 
oximetry. The measurements were repeated 5 minutes later to ensure 
stability. NaNO2 was then infused intravenously over 5 minutes, and 
the above hemodynamic measurements were repeated at the end of 
the infusion. Blood pressure, ECG, and oxygen saturation were moni-
tored continuously.
Blood Samples
Venous blood samples were taken at baseline and after infusion of 
NaNO2 for methemoglobin, plasma nitrite/nitrate, and total nitroso 
species (RXNO) measurements. Blood for determination of venous 
plasma nitrite, nitrate, and RXNO concentrations were collected into 
EDTA tubes and immediately centrifuged (800g for 10 minutes at 
4°C). Samples were stored at −80°C before assay. Plasma nitrite, ni-
trate, and RXNO concentrations were determined, after addition of 
N-ethylmaleimide (10 mmol/L final concentrations) during the thaw-
ing process, via high-performance liquid chromatography and chemi-
luminescence as previously described.13
Statistical Analysis
Data are presented as mean±SD. Hemodynamic comparisons were 
performed by paired 1-tailed Student t test. Changes from baseline 
between treatment groups were performed by unpaired 1-tailed 
Student t test; a P value of <0.05 was taken to indicate statistical sig-
nificance. Changes in TSG (ie, left ventricular end-diastolic pressure-
right ventricular end-diastolic pressure) during NaNO2 infusion were 
estimated as change in PCWP–RAP.14 Statistical analysis was under-
taken using Prism software (version 5.0, GraphPad Software, CA).
Results
Demographics
The demographics for the entire cohort and the groups receiv-
ing 10 μg/kg/min (group 1) and 50 μg/kg/min (group 2) are 
Table 1. Demographics and Cardiovascular Disease Profile of 
the Heart Failure Patients
Entire  
Cohort 
(25)
Group 1 (n=8)  
10 μg/kg/min nitrite
Group 2 (n=17)  
50 μg/kg/min nitrite
Demographic
  Age, y 48±13 50±12 47±14
  Gender, m 18 7 11
  Body mass  
index, kg/m2
26.6±3.84 26.1±4.02 26.7±3.87
Pathogenesis of  
heart failure
  Dilated 
cardiomyopathy
15 6 9
  Ischemic 
cardiomyopathy
6 2 4
  Valvular heart  
disease
1 … 1
  Other 3 … 3
Medication
  ACEI/AT1 receptor 
blocker
25 8 17
  Beta-blocker 17 6 11
  Loop diruretic 23 6 17
  Aldosterone  
antagonist
14 2 12
Entire cohort (group 1 and 2; n=25). Group 1, 10 μg/kg/min nitrite heart failure 
patient group (n=8); and Group 2, 50 μg/kg/min nitrite heart failure patient 
group (n=17). All continuous variables are expressed as mean±SD. ACEI indicates 
angiotensin-converting enzyme inhibitor; and AT1, angiotensin receptor antagonist.
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shown in Table 1. Hemodynamic parameters are shown in 
Table 2. At baseline (ie, before infusion of sodium nitrite), 
hemodynamic parameters were similar in group 1 and group 
2, except heart rate was significantly higher in group 2 
(P=0.046) and systemic vascular resistance (SVR) was sig-
nificantly higher in group 2 (P=0.03).
Blood Pressure and Heart Rate Effects
As shown in Table 2, there was no statistically significant 
change in heart rate at either infusion rate. 10 μg/kg/min 
NaNO2 infusion did not significantly affect MABP, whereas 
in contrast 50 μg/kg/min of NaNO2 infusion modestly but sig-
nificantly decreased MABP by a mean of 4 mm Hg (P<0.004).
Nitrite Infusion Decreases Pulmonary and Systemic 
Vascular Resistance
As shown in Table 2, 50 μg/kg/min of NaNO2 infusion signifi-
cantly decreased PVR by 29% (P=0.03), and systemic vascular 
resistance fell by 12% (P=0.01; Table 2). Arterial elastance fell 
by 18% from 1.95±0.71 to 1.60±0.53 mm Hg/mL (P=0.002; 
Table 2). Infusion of 10 μg/kg/min NaNO2 infusion resulted 
in directionally similar effects, but these were not significant.
Nitrite Reduces Pulmonary Capillary Wedge 
Pressure and Right Atrial Pressure and Improves 
Cardiac Output
As shown in Table 2, in the 50 μg/kg/min group, there was 
a significant reduction in mean RAP by 40% and PCWP fell 
by 7% (nonsignificant). Consequently, estimated TSG sig-
nificantly increased by a mean of 3 mm Hg. CO significantly 
increased by 13% and SV significantly increased by 14%. 10 
μg/kg/min NaNO2 infusion resulted in a significant increase in 
SV by 15.5%, but the increase in CO was not significant. As 
shown in the Figure, the change in SV during 50 μg/kg/min 
nitrite infusion was significantly correlated with the change 
in estimated TSG (r=0.67; P=0.003). Mean arterial oxygen 
saturation remained unchanged at either infusion rate.
Impact of Baseline SVR on SV Response to IV Nitrite
Patients receiving the higher dose infusion regime were 
divided into those with SVR above versus below the mean 
for the group at baseline (33.17 wood units). There was no 
significant difference in the change in LV SV between these 2 
groups (9.9+8.5 versus 5.1+8.8 mL; P=0.3).
Changes in SV in Patients With PCWP > and <15 
mm Hg
In 11 patients with PCWP >15 mm Hg (mean 22.4±8.0 
mm Hg), infusion of sodium nitrite at the higher con-
centration increased SV by 20% from 43.22±21.5 to 
51.84±23.6 mL (P=0.003), whereas in those with PCWP 
<15 mm Hg (n=6), there was no significant change in SV 
(62.5±22.02 to 65.1±21.09 mL; P=0.24). Estimated TSG 
Table 2. The Effect of Short-Term Sodium Nitrite Infusion on Cardiac and Pulmonary Hemodynamics in Heart Failure Patients
Hemodynamics
Group 1 (n=8) Group 2 (n=17)
∆ 10 vs 50 μg, 
P ValueBaseline 10 μg/kg P Value
Mean ∆ From 
Baseline Baseline 50 μg/kg P Value
Mean ∆ From 
Baseline
Heart rate, beats 
per minute
67±9 65±9 0.07 −2.5±4.3 79±18 78±18 0.12 −0.8±2.8 0.13
MABP, mm Hg 80±12 80±11 0.49 −0.04±7 78±7 74±6 0.004* −3±4 0.09
SVR, Wood units 25.6±7.3 23.7±8.9 0.097 −1.92±3.8 33.2±9.2 29.1±6.7 0.01* −4.0±6.6 0.21
PVR, Wood units 2.3±1.3 1.8±0.7† 0.28 −0.3±1.3† 2.1±1.4 1.5±0.9 0.03* −0.6±1.1 0.32
RAP, mm Hg 14.0±8.6 9.5±5.8† 0.31 −2.8±10.1† 9.8±7.7 5.9±5.9 0.007‡ −3.9±5.8 0.38
CO, L/min 3.4±1.2 3.7±1.1 0.08 0.4±0.7 3.9±1.0 4.4±0.9 0.003‡ 0.5±0.6 0.32
SV, mL 51.1±18.7 59.0±21.2 0.01* 7.9±7.9 51.1±20.8 58.1±19.6 0.002‡ 6.9±8.5 0.40
PCWP, mm Hg 21.5±10.2 18.6±9.4† 0.13 −2.4±5.1† 18.7±10.2 17.7±10.3 0.28 −0.94±6.4 0.3
TSG, mm Hg 7.5±9.0 13.8±12.8† 0.14 4.8±8.6† 8.8±7.2 11.8±7.0 0.002‡ 3.0±3.7 0.25
Ea, mm Hg/mL 2.09±0.66 1.86±0.71 0.08 −0.23±0.4 1.95±0.71 1.60±0.53 0.002‡ −0.35±0.4 0.25
Arterial oxygen 
saturation, %
96.13±2.42 95.38±1.69 0.14 −0.75±1.83 97.29±2.50 96.76±2.51 0.19 −0.53±2.45 0.41
∆ 10 vs 50 μg, changes between treatment groups from baseline. Group 1, 10 μg/kg/min (n=8); and Group 2, 50 μg/kg/min (n=17). Data expressed as mean±SD. 
CO indicates cardiac output measured by FICK; Ea, arterial elastance; MABP, mean arterial blood pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary 
vascular resistance; RAP, right atrial pressure; SVR, systemic vascular resistance; and TSG, transeptal gradient.
*P<0.05.
†Based on 7 patients because of 1 missing value.
‡P<0.001. 
Figure.  Changes in estimated trans-septal gradient positively 
correlated with change in stroke volume (SV) in all patients 
infused with 50 μg/kg/min sodium nitrite.
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increased by 3.6 mm Hg in the high PCWP subgroup (from 
11.9±6.8 to 15.5±4.7 mm Hg; P=0.005) and by 2 mm Hg in 
the lower PCWP subgroup (from 3.2±3.4 to 5.2±5.3; P=0.13).
Short-Term Intravenous Nitrite Infusion Increases 
Circulating NO Metabolites
As shown in Table 3, 10 μg/kg/min NaNO2 infusion did not 
significantly alter plasma RXNO or plasma nitrate concen-
trations but significantly increased plasma nitrite. 50 μg/kg/
min NaNO2 infusion significantly increased all measured NO 
metabolites from baseline.
Methemoglobinemia Increased Within Safe Levels
As shown in Table 3, a modest dose-dependent increase in 
methemoglobin was observed after 10 and 50 μg/kg/min of 
sodium nitrite.
Discussion
Herein, we demonstrate for the first time the short-term 
hemodynamic effects of intravenous NaNO2 in patients with 
severe but stable chronic HF. As hypothesized, effects were 
favourable, with an increase in LV SV and CO and with only 
a minor reduction in blood pressure. As anticipated, there was 
a substantial reduction in PVR, but only a modest reduction 
in SVR. The hemodynamic effects were statistically signifi-
cant at 50 μg/kg/min. At 10 μg/kg/min, directionally similar 
effects were observed, but apart from a significant increase in 
SV, these were nonsignificant. There was no significant differ-
ence in the magnitude of the hemodynamic effects seen with 
10 versus 50 μg/kg/min, but given the smaller sample size of 
the former group, caution should be exercised in drawing con-
clusions about the dose-response relationship.
The patients studied had severe but stable chronic HF and 
were undergoing assessment as candidates for cardiac trans-
plantation. We chose a brief (5 minute) infusion regime as a 
proof of concept for safety reasons because this was a first-
in-man study of systemic nitrite infusion in chronic HF. The 
effects were observed at the 50 μg/kg/min infusion rate and, 
although directionally similar, were not significant at the 
10 μg/kg/min infusion rate, although the latter may partly 
be because of a smaller sample size in the lower dose group. 
Although only modest increases in methemoglobin levels were 
observed with either dose, based on studies in healthy volun-
teers, sustained infusion of 50 μg/kg/min would be expected 
to cause marked (and potentially dangerous) methemoglo-
binemia. However, we have subsequently undertaken pilot 
studies (data not shown) in patients with chronic HF (without 
hemodynamic assessment) and have demonstrated that sus-
tained infusion of 10 μg/kg/min caused a progressive increase 
in plasma nitrite and RXNO, such that by 3 hours these levels 
were almost as high as we observed in the present study with 
50 μg/kg/min infused over 5 minutes, without inducing dan-
gerous methemoglobinemia and without inducing significant 
hypotension. In a study in healthy volunteers, Pluta and col-
leagues reported that sustained infusion (several hours) of 
doses of ≈5 μg/kg/min sodium nitrite resulted in significant 
hypotension and methemoglobin >5%.15 Further studies are 
therefore warranted to evaluate whether sustained infusion of 
lower doses of NaNO2 would have similar favorable hemody-
namic effects to those observed with short-term infusion of 50 
μg/kg/min without inducing methemoglobinemia or resulting 
in hypotension. Although patients with decompensated HF 
but without frank pulmonary edema and associated arterial 
hypoxemia may be expected to exhibit preferential dilation of 
capacitance vessels and pulmonary vasculature, in the latter 
setting, substantial resistance vessel dilation might be antici-
pated with an attendant fall in blood pressure.6 Preferential 
vasodilation of pulmonary vessels to underventilated alveoli 
has the potential to worsen ventilation–perfusion matching; 
however, we observed no reduction in arterial oxygen satura-
tions in this study, despite a substantial fall in PVR.
The increase in SV in the face of a reduced PCWP repre-
sents an apparent descending limb of the Starling curve. This 
is because in severe chronic HF, despite high left ventricular 
end diastolic pressures, LV filling is impeded by external con-
straint from the stretched pericardium (pericardial constraint) 
and via the interventricular septum from the right ventricle 
(DVI),16 usually in the context of pulmonary hypertension. 
By preferentially dilating the systemic capacitance and pul-
monary resistance vessels,10 nitrite may be expected to reduce 
RV volume and hence pericardial stretch, thereby augment-
ing LV filling and SV. Consistent with relief of DVI as an 
Table 3. Plasma Concentrations of Nitrite, Nitrate, and Total Nitroso Species (RXNO) and Methemoglobin (MetHb) Content of 
Venous Blood of Heart Failure Patients at Baseline and Post Sodium Nitrite Infusion
Blood analysis
Group 1 (n=8) Group 2 (n=17)
∆ 10 vs 50 μg, 
P ValueBaseline 10 μg/kg P Value
Mean ∆ From 
Baseline Baseline 50 μg/kg P Value
Mean ∆ From 
Baseline
Nitrite, μM 1.29±0.52 4.38±2.16 0.005* 3.09±2.25 1.64±3.0 16.13±10.9† 0.0001‡ 14.29±8.97† 0.002*
Nitrate, μM 26.87±10.5 27.61±9.76 0.17 0.75±1.92 21.55±11.79† 35.51±14.0§ 0.0001‡ 15.58±6.19§ 0.0001‡
Nitroso species 
(RXNO), nM
13.76±8.0 10.93±2.96 0.14 −2.83±5.76 12.92±4.83 40.27±21.65† 0.0001‡ 27.86±19.27† 0.0008‡
MetHb, % 0.44±0.13 0.61±0.17 0.008* 0.18±0.16 0.33±0.12 1.02±0.54† 0.0001‡ 0.68±0.57† 0.01║
∆ 10 vs 50 μg, changes between treatment groups from baseline. Group 1, 10 μg/kg/min (n=8); and Group 2, 50 μg/kg/min (n=17). Data expressed as mean±SD.
*P<0.001.
†Based on 16 patients because of 1 missing value.
‡P<0.0001.
§Based on 15 patients.
║P<0.05.
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important mechanism, the increase in SV was only observed 
in the group of patients with PCWP >15 mm Hg—a cutoff that 
we have previously shown to identify HF patients with sig-
nificant DVI.16 In this subgroup, the SV increased by 20%.16 
In accordance with this concept, the reduction in RA pressure 
(an indirect measure of both RVEDP and pericardial pres-
sure)17 was greater than the reduction in PCWP; hence, the 
estimated TSG (ie, the pressure gradient across the interven-
tricular septum at end diastole)—a measure of the true filling 
pressure of the LV at end diastole18—was increased by sodium 
nitrite. Furthermore, the increase in SV was significantly cor-
related with the change in estimated TSG. We cannot exclude 
a significant direct myocardial effect of nitrite as a contribu-
tory mechanism. In the vertebrate, heart nitrite positively 
modulated the Frank–Starling response via a NO-dependent 
mechanism.19 In contrast, another study reported negative ino-
tropic effects via a NO/cGMP-dependent mechanism in the 
Langendorff rat heart.20 In a recent study, chronic oral inor-
ganic nitrite supplementation ameliorated the development of 
HF in a murine thoracic aortic constriction model in associa-
tion with an upregulation of cytoprotective pathways.21
Intravenous sodium nitroprusside is sometimes used in the 
treatment of acute decompensated HF. Fifer et al reported the 
effects of intravenous sodium nitroprusside in patients with 
severe CHF.22 Cardiac index increased substantially (by 25%), 
but systemic vascular resistance also fell substantially (by 
25%) and MABP fell by 13 mm Hg. The reduction in mean 
PCWP (by 14 mm Hg) was substantially greater than that of 
RA pressure (by 4 mm Hg), that is, mean TSG fell substan-
tially, which suggests that relief of DVI was not an important 
mechanism of the increase in CO.22
Organic nitrates are more commonly used in the treatment 
of decompensated HF. Indeed intravenous isosorbide dinitrate 
has been shown to be superior to either intravenous furose-
mide23 or positive airways pressure24 in the management of 
patients with acute pulmonary edema. These agents dilate 
capacitance and resistance vessels.25 At lower doses, the vaso-
dilator effects of glyceryl trinitrate (GTN) are predominantly 
on capacitance vessels, but at higher doses, effects on vascu-
lar resistance are increasingly observed.26 Rabinowitz et al 
reported the hemodynamic effects of intravenous isosorbide 
dinitrate in patients with decompensated HF. CO increased 
similarly to our study (by 17%), but the reduction in systemic 
vascular resistance (35%) and the fall in mean arterial pres-
sure (10 mm Hg) were substantially more than we observed 
with sodium nitrite. The increase in CO was substantially 
greater in those patients with high resting SVR, suggesting 
that afterload reduction may have been an important contribu-
tor to the increase in CO.27 Armstrong et al reported the effects 
of GTN infusion in patients with severe CHF. CO increased by 
≈20%. Systemic vascular resistance fell by ≈21% and MABP 
by 7 mm Hg. In contrast to our findings with nitrite, the fall 
in PCWP (by 8 mm Hg) was greater than that of RAP (by 5 
mm Hg), indicating that overall the estimated TSG fell with 
this therapy rather than the increase we observed with sodium 
nitrite infusion.28 However, Dupuis and colleagues showed 
that during sustained (72 hour) infusion of GTN, SV increased 
in a subgroup of patients in whom LV end diastolic volume 
increased and fell in those in whom LV end diastolic volume 
fell during GTN infusion.29 These data suggest that GTN may 
relieve DVI in some patients with decompensated HF, but this 
effect seems less marked than we have observed in this study 
with intravenous sodium nitrite.
The reduction in SVR (by 12%) observed in the present study 
was substantially less than that observed in the above studies 
with either sodium nitroprusside (25%)22 or isosorbide dinitrate 
(35%),27 suggesting that this may play a less important role in 
the increase in CO with sodium nitroprusside. Furthermore, in 
our study, there was no significant difference in the change in 
SV induced by sodium nitrite between those with higher versus 
lower systemic vascular resistance before infusion. However, 
left ventricular afterload has a pulsatile component, as well as 
a static component, and changes in SVR do not therefore com-
pletely describe effects on LV afterload. GTN has previously 
been shown to reduce wave reflection.2 In the present study, 
the reduction in arterial elastance (a measure of LV afterload 
encompassing both static and pulsatile components) was 18%.
In summary, our data are consistent with an effect of sodium 
nitrite on SV largely mediated via relief of DVI because of 
relatively selective and potent dilation of capacitance ves-
sels and pulmonary vasculature.6,10 Based on changes in esti-
mated TSG, this mechanism may be less marked with organic 
nitrates and sodium nitroprusside, and changes in LV after-
load may be relatively more important for these drugs than 
with sodium nitrite.
Nitrite has further characteristics that may make it a poten-
tially attractive agent for the treatment of decompensated 
HF and therefore worthy of further investigation based on 
the findings of this short-term proof of concept/safety study. 
Some patients with HF exhibit nitrate (and NO) resistance, 
potentially because of increased oxidative stress.30–32 In con-
trast, during intra-arterial infusion of NaNO2, we observed 
an enhanced response in patients with HF versus controls.11 
Furthermore, organic nitrate therapy is subject to the rapid 
development of tolerance. In primates, tolerance was not 
observed with sodium nitrite.7
Study Limitations
Although nitrite infusion resulted in clear increases in plasma 
nitrite concentrations at both infusion rates, only the one 
associated with a concomitant elevation in circulating RXNO 
levels increased CO. This suggests that, in this setting, the 
beneficial hemodynamic effects of nitrite are associated either 
with the involvement of a post-translational modification of 
cardiac tissue proteins33 or some form of NO delivery from 
a circulating plasma storage form of NO (perhaps nitrosated 
albumin)13 to heart and vasculature. Although intriguing, 
establishing the mechanistic basis for this observation was 
well beyond the scope of the present study.
Clinical Implications: Future Studies
This is the first-in-man proof of concept/safety study dem-
onstrating a potentially favorable hemodynamic response to 
short-term NaNO2 infusion in patients with severe chronic 
HF. Further studies are warranted to assess longer term safety 
and hemodynamic efficacy, and if these are confirmed, this 
may warrant a randomized controlled trial of sodium nitrite 
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versus current therapy in decompensated HF focussing on 
hard end points. Sodium nitrite could be administered either 
intravenously in such studies or perhaps in nebulized form,34 
the latter may be particularly attractive in decompensated HF. 
Unfortunately, several therapies shown to have attractive acute 
hemodynamic profiles have failed in phase 3 trials in decom-
pensated HF.35 However, a notable exception was a recent 
study of Serelaxin in patients with acute HF with dyspnea, in 
which a significant reduction in dyspnea score and 6 month 
mortality was reported.36
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CLINICAL PERSPECTIVE
Nitrite exhibits hypoxia dependent vasodilator properties. We therefore hypothesized that by preferential dilation of venous 
capacitance vessels and pulmonary arterioles (low ambient oxygen) with lesser effects on systemic arterioles (higher ambi-
ent oxygen tension), sodium nitrite would increase stroke volume in patients with heart failure by relief of pericardial 
constraint and diastolic ventricular interaction. We therefore performed a short-term (5 minute) proof of concept/safety 
study in 25 patients with severe but stable chronic heart failure who were undergoing precardiac transplant assessment. As 
hypothesized, there was a marked reduction in pulmonary vascular resistance and right atrial pressure with a lesser fall in 
pulmonary capillary wedge pressure and a modest reduction in systemic vascular resistance. Estimated trans-septal gradient 
(ie, pulmonary capillary wedge pressure– right atrial pressure) therefore increased, and this was correlated with the observed 
increase in stroke volume consistent with relief of diastolic ventricular interaction as an important mechanism. This is a 
potentially attractive hemodynamic profile in decompensated heart failure, but further studies are required to assess the 
safety and efficacy of longer-term infusion.
 at UNIVERSITY OF BIRMINGHAM on January 20, 2016http://circheartfailure.ahajournals.org/Downloaded from 
Frenneaux
Bernadette O. Fernandez, Robert S. Bonser, Martin Feelisch, Melanie Madhani and Michael P. 
Julian O.M. Ormerod, Sayqa Arif, Majid Mukadam, Jonathan D.W. Evans, Roger Beadle,
Hemodynamics in Heart Failure Patients
Short-Term Intravenous Sodium Nitrite Infusion Improves Cardiac and Pulmonary
Print ISSN: 1941-3289. Online ISSN: 1941-3297 
Copyright © 2015 American Heart Association, Inc. All rights reserved.
75231
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TXCirculation: Heart Failure 
doi: 10.1161/CIRCHEARTFAILURE.114.001716
2015;8:565-571; originally published online April 2, 2015;Circ Heart Fail. 
Free via Open Access 
 http://circheartfailure.ahajournals.org/content/8/3/565
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://circheartfailure.ahajournals.org//subscriptions/
is online at: Circulation: Heart Failure  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer about this process is available in the 
located, click Request Permissions in the middle column of the Web page under Services. Further information 
isthe Editorial Office. Once the online version of the published article for which permission is being requested 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, notCirculation: Heart Failurein
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at UNIVERSITY OF BIRMINGHAM on January 20, 2016http://circheartfailure.ahajournals.org/Downloaded from 
